Moral,Prudential,and Political Arguments about Harm Reduction

1. Urbina I. (2007, May 28) Alone in a city's AIDS battle, hoping for a backup. New York Times, Section 1.

2. USSC (2003) Federal Sentencing Guideline Manual. Washington, DC: Department of Justice.

3. Liptak A. (2004, September 12) Long Term in Drug Case Fuels Debate on Sentencing. New York Times, Section 20.

4. Rosenberg T. (2007, June 17) When Is a Pain Doctor a Drug Pusher? New York Times magazine.

5. Greenhouse L. (2007, December 11) Court restores sentencing powers of federal judges. New York Times, Section 1.

6. MacCoun R. & Reuter P. (2001) Drug war heresies: Learning from other vices, times and places. New York: Cambridge University Press.

7. Feinberg J. (1989) Harm to Self. Moral Limits of the Criminal Law, 3. New York: Oxford University Press.

8. Kleiman M. (1993) Against Excess: Drug Policy for Results. New York: Basic Books.

9. Reuter P. & Pollack H. (2006) How much can treatment reduce national drug problems? Addiction 101(3):341–347.

10. Kleiman M. (1998) Drugs and drug policy: The case for a slow fix. Science and Technology XV(1).

11. Des Jarlais D. Friedman S. & Ward T. (1993) Harm reduction: A public health response to the AIDS epidemic among injecting drug users. Annual Review of Public Health 14:413–450.

12. Public consultation—proposals to make lawful the supplly of specific items of drugs paraphernalia to drug users. (2002) London: Home Office.

13. Wren C. (1998, June 18) Drug Policy Official Warns Panel of Effort to Legalize Drugs. New York Times.

14. Goode E. (2003 April 18) Certain words can trip up AIDS grants, scientists say. New York Times Section A10.

15. Kaiser J. (2003) NIH roiled by inquiries over grants hit list. Science 758.

16. TVC. (2003) TVC Response Letter to Congressman Waxman on NIH Grants. Washington, DC: Traditional Values Coalition.

17. Herbert R. (2003, November 3) The big chill at the lab. New York Times, Section 19.

18. Souder M. (2003) Harm Reduction Causes Harm. New York: Drug Policy Alliance.

19. Kaplan E. & Soloschatz D. (1993) How Many Drug Injectors Are There In New Haven? Answers From AIDS Data. Mathematical and Computer Modelling 17(2):109–115.

20. Lenton S. & Hargreaves K. (2000) Should we conduct a trial of distributing naloxone to heroin users for peer administration to prevent fatal overdose? Medical Journal of Australia 173(5):260–263.

21. Harding W. Caudill B. & Moore B. (2001) Do companions of designated drivers drink excessively? Journal of Substance Abuse 13(4):505–514.

22. Peltzman S. (1975) The effects of automobile safety regulation. Journal of Political Economy 83(4):677–726.

23. IOM. (2001) Clearing the smoke: Assessing the science base for tobacco harm reduction. Washington, DC: National Academy Press.

24. Pollay R. & Dewhirst T. (2002) The dark side of marketing seemingly “Light” cigarettes: Successful images and failed fact. Tobacco Control, 11:i18–i31.

25. Warner K. (2002) Tobacco harm reduction: Promise and perils. Nicotine and Tobacco Research 4(2):S61–S71.

26. Heimer R. Kaplan E. Khoshnood K. Jariwala B. & Cadman E. (1993) Needle exchange decreases the prevalence of HIV-1 proviral DNA in returned syringes in New Haven, Connecticut. American Journal of Medicine 95(2):214–220.

27. Kaplan E. & Heimer R. (1992) A model-based estimate of HIV infectivity via needle sharing. Journal of AIDS 5(11):1116–1118.

28. Kaplan E. & Heimer R. (1994) A circulation theory of needle exchange. AIDS 8(5):567–574.

29. IOM. (2000) No time to lose: Making the most of HIV prevention. Washington, DC: National Academy Press.

30. IOM. (1995) Preventing HIV transmission: the role of sterile needles and bleach. Washington, DC: Institute of Medicine, National Academy Press.

31. Choi K. & Coates T. (1994) Prevention of HIV Infection. AIDS 8(10):1371–1389.

32. Waiters J. Estilo M. Clark G. & Lorvick J. (1994) Syringe and needle exchange as HIV/AIDS prevention for injection drug users. JAMA 271(2):115–120.

33. GAO. (1993) Needle Exchange Programs: Research Suggests Promise as an AIDS Prevention Strategy. Washington, DC: General Accounting Office. Report No.: GAO/HRG-93-60.

34. Lurie P. Reingold A. L. Browser B. Chen D. Foley J. Guydish J. (1993) The Public Health Impact of Needle Exchange Programs in the United States and Abroad. San Francisco, CA: Institute for Health Policy Studies, University of California, San Francisco, CA.

35. Lurie P. & Drucker E. (1997) An opportunity lost: HIV infections associated with lack of a national needle-exchange program in the USA. Lancet 349(9052):604–608.

36. Kaplan E. H. (1995) Economic Analysis of Needle Exchange. AIDS 9(10):1113–1119.

37. Satel S. (2000) How political correctness is corrupting medicine. New York: Basic Books.

38. IOM. (2000) No time to lose: Getting more from HIV prevention. Washington, DC: National Academy Press.

39. Wren C. (1998, March 23) White House Drug and AIDS Advisors Differ on Needle Exchange. New York Times Section A10.

40. Richardson L. (1998, April 22) U.S. Refusal to Finance Needle Exchanges Angers Agencies. New York Times Section A27.

41. Zerhouni E. (2004, October 7) Letter from NIH Director Dr. Elias A. Zerhouni to Reps Henry A. Waxman and Eliza E. Cummings. Washington, DC: National Institutes of Health.

42. Fairchild A & Bayer R. (1999) Uses and abuses of Tuskegee. Science 284(5416):919–921.

43. Fisher D. Fenaughty A. Cagle H. & Wells R. (2003) Needle exchange and injection drug use frequency: A randomized clinical trial. Journal of Acquired Immune Deficiency Syndromes 33(2):199–205.

44. Strathdee S. (2004) ALIVE Team Letter to NIH. Baltimore: Drug Policy Alliance.

45. Bogart L. Kral A. Scott A. Anderson R. Flynn N. Gilbert M. (2005) Condom attitudes and behaviors among injection drug users participating in California syringe exchange programs. AIDS and Behavior 9(4):423–432.

46. Pollack H. (2001) Can we protect drug users from Hepatitis C? Journal of Policy Analysis and Management 20(2):358–364.

47. Moss A. & Hahn J. (1999) Invited commentary: Needle exchange—no help for hepatitis? American Journal of Epidemiology 149(3):214–216.

48. Coutinho R. (1998) HIV and Hepatitis C Among Injecting Drug Users: Success in Preventing HIV Has Not Been Mirrored for Hepatitis C. British Medical Journal 317(7156):424–425.

49. Hagan H. McGough J. P. Thiede H. Weiss N. S. Hopkins S. & Alexander E. R. (1999) Syringe exchange and risk of infection from hepatitis B and C viruses. American Journal of Epidemiology 149(3):203–213.

50. Broers B. Junet C. Bourquin M. Deglon J. Perrin L. & Hirschel B. (1998) Prevalence and incidence rate of HIV, hepatitis B and C among drug users on methadone maintenance treatment in Geneva between 1988 and 1995. AIDS 12(15):2059–2066.

51. Crofts N. Nigro L. Oman K. Stevenson E. & Sherman J. (1997) Methadone Maintenance and Hepatitis C Virus Infection Among Injecting Drug Users. Addiction 92(8):999–1005.

52. Garfein R. Doherty M. Monterroso E. Thomas D. Nelson K. & Vlahov D. (1998) Prevalence and Incidence of Hepatitis C Virus Infection Among Young Injection Drug Users. Journal of Acquired immune Deficiency Syndromes and Human Retrovirology 18(S1):S11–S19.

53. Mansson A. Moestrup T. Nordenfelt E. & Widell A. (2000) Continued transmission of hepatitis B and C viruses, but no transmission of human immunodeficiency virus among intravenous drug users participating in a syringe/needle exchange program. Scandinavian Journal of Infectious Diseases 32(3):253–258.

54. Trepo C. & Pradat P. (1999) Hepatitis C virus infection in Western Europe. Journal of Hepatology 31(S1):80–83.

55. van Beek I. Dwyer R. Dore G. Luo K. & Kaldor J. (1998) Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: Retrospective cohort study. British Medical Journal 317(7156):433–437.

56. Scott G. Thomas S. Pollack H. & Ray B. (2006) Observed Patterns of Illicit Opiate Overdose Deaths in Chicago, 1999–2003. Journal of Urban Health.

57. Heimer R. (1998) Can syringe exchange serve as a conduit to substance abuse treatment? Journal of Substance Abuse Treatment 15(3):183–191.

58. Vlahov D. Junge B. Brookmeyer R. Cohn S. Riley E. & Armenian H. (1997) Reductions in high-risk drug use behaviors among participants in the Baltimore needle exchange program. Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology 16(5):400–406.

59. Sullivan P. Drake A. & Sanchez T. (2007) Prevalence of treatment optimism-related risk behavior and associated factors among men who have sex with men in 11 states, 2000–2001. AIDS and Behavior 11(1):123–129.

60. Jaffe H. Valdiserri R. & DeCock K. (2007) The reemerging HIV/AIDS epidemic in men who have sex with men. Journal of the American Medical Association 298(20):2412–2414.

61. Lurie P. (1995) When science and politics collide: The federal response to needle-exchange programs. Bulletin of the New York Academy of Medicine 72(2):380–396.

62. Zonana V. (1989, July 20) Sullivan shoots down plan to supply needles. Los Angeles Times Section 13.

63. Sullivan L. (1999, July 28) Letter to the Honorable Dennis Hastert. Atlanta, GA: Morehouse School of Medicine.

64. Cohen C. (1999) The boundaries of blackness: AIDS and the breakdown of black politics.

65. Rangel C. (1989, April 28) Needle exchanges hurt the fight against drugs. USA Today Section A10.

66. Woods I. (1998) Bringing harm reduction to the black community: There's a fire in my house and you're telling me to rearrange my furniture? In: G. M. editor. Harm reduction: pragmatic strategies for managing high-risk behaviors. New York: Guilford Press; p. 301–326.

67. Dalton H. (1989) AIDS in blackface. Daedalus 118:205–229.

68. Massing M. (1998) The fix. New York: Simon and Schuster.

69. Basu A. Paltiel A. & Pollack H. (2007) Social costs of robbery and the cost-effectiveness of substance abuse treatment. Health Economics.

70. Healy P. & Altman L. (2007, November 27) Clinton to Offer an AIDS Policy, Joining Her Main Rivals. New York Times.

71. MacCoun R. (1998) Toward a psychology of harm reduction. American Psychologist 53(11):1199–1208.

72. MacCoun R. (2005) Sex, drugs, and skateboarding: public support for prevalence reduction vs. harm reduction. Berkeley, CA.

73. HRW. (1991) No escape: Male rape in U.S. prisons. Human Rights Watch.

74. Hirschman A. (1991) The Rhetoric of Reaction: Perversity, Futility, Jeopardy. Cambridge, MA: Belknap Press.

75. Torgerson D. (1986) Between knowledge and politics: Three faces of policy analysis. Policy Sciences 19:31–59.

76. Heimer R. (1998) Can syringe exchange serve as a conduit to substance abuse treatment? Journal of Substance Abuse Treatment 15(3):183–191.

77. Blendon R. & Young J. (1998) The public and the war on illicit drugs. Journal of the American Medical Association 279(11):827–832.

78. Schwartzenegger A. (2004) [Letter to California State Senate]. Sacramento, CA: Governor's Office.